Biota Holdings Ltd. (BTA.AU) said Friday the Australian government will spend A$43 million to almost double its Relenza stockpile.

Biota said that the government will buy an extra 1.6 million courses to bolster its supplies of antiviral drugs to treat pandemic influenza.

The drug is made by GlaxoSmithKline PLC (GSK) under license and Biota earns a 10% royalty on all Australian sales of Relenza, it said in a statement.

On completion of the contract, the stockpile will include 3.4 million courses of Relenza, which comprises one-third of the total stockpile of influenza antivirals, Biota said.

-By Andrew Harrison, Dow Jones Newswires; 61-3-9292-2095; andrew.harrison@dowjones.com
Biota Holdings (ASX:BTA)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Biota Holdings Charts.
Biota Holdings (ASX:BTA)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Biota Holdings Charts.